Global Patterns of Fatalities With Toxicological Detection of Novel Psychoactive Substances: A Systematic Review and Meta-analysis
Forensic Medicine, All India Institute of Medical Sciences, New Delhi, IND
Forensic Medicine, Shri Mata Vaishno Devi Institute of Medical Excellence, Katra, IND
Physiology, Shri Mata Vaishno Devi Institute of Medical Excellence, Katra, IND
Forensic Medicine, Guru Gobind Singh Medical College, Faridkot, IND
Hospital Administration, Shri Mata Vaishno Devi Institute of Medical Excellence, Katra, IND
General Physician, Department of Health and Family Welfare, Amritsar, IND
Neuropsychiatry, Bhatia Neuropsychiatric Hospital, Amritsar, IND
Health and Family Welfare, Ayushman Arogya Kendra Focal Point, Jalandhar, IND
Medicine, Government Medical College, Amritsar, IND
Abstract
Novel psychoactive substances (NPS) have rapidly diversified the global drug market, creating escalating challenges for forensic toxicology and mortality surveillance. While regional reports have described fatal NPS involvement, the global prevalence and temporal trends of NPS detection in fatalities are insufficiently quantified.
A search following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines was performed in PubMed, Embase, Scopus, and Web of Science (January 2008-May 2025), supplemented by screening a repository of 96 primary studies, to find studies with toxicologically confirmed detection of NPS in fatalities. We included autopsy or surveillance datasets with analytical confirmation by gas chromatography-mass spectrometry, liquid chromatography-tandem mass spectrometry (LC-MS/MS), high-resolution mass spectrometry, or nuclear magnetic resonance spectroscopy. The primary outcome was the proportion of NPS-positive cases among all forensic cases undergoing comprehensive toxicological analysis. Random-effects meta-analysis estimated pooled proportions and subgroup trends. Heterogeneity, I², meta-regression by year, region, and analytical method, and publication bias by Egger's test were assessed.
Of 621 records screened (525 from databases and 96 from supplementary repository), 125 studies met the inclusion criteria and 86 contributed to quantitative synthesis. The pooled global proportion of fatalities with NPS detection was 7.8% (95% CI: 6.2%-9.8%), with a marked increase from 2.5% (2008-2014) to 9.3% (2015-2025). Synthetic opioids predominated (3.4%), followed by cathinones (2.1%) and cannabinoids (1.6%). North America showed the highest pooled proportion (9.4%), followed by Europe (6.9%). Meta-regression showed that later study year (β = 0.12, p = 0.004) and LC-MS/MS use (β = 0.17, p = 0.019) independently predicted higher detection proportions. Publication bias was not significant (p = 0.27).
The detection of NPS in fatalities has increased globally, driven by potent synthetic opioids and enhanced analytical detection. Enhanced forensic capacity, standardization of toxicological panels, and real-time surveillance need to be developed to mitigate the emerging global risks.
Untitled section
Keywords: cannabinoids, cathinones, drug-related mortality, forensic toxicology, novel psychoactive substances, synthetic opioids
Article notes
Untitled section
Accepted 2025 Dec 18; Collection date 2025 Dec.
Introduction and background
The emergence of novel psychoactive substances (NPS) has profoundly changed the landscape of global drug use over the past two decades. These substances are synthetic compounds that have been designed to mimic the effects of traditional illicit drugs yet evade existing legal frameworks. They include various chemical classes such as synthetic cannabinoids, cathinones, opioids, phenethylamines, and tryptamines associated with unpredictable pharmacodynamics and toxicological profiles [1]. Their rapid proliferation has outpaced both legislative control and analytical detection capacity, creating massive problems for forensic and public health systems worldwide [2,3].
Since the late 2000s, NPS have transitioned from niche recreational use to major contributors to drug-related morbidity and mortality, with synthetic opioids, particularly nitazenes and fentanyl analogs, emerging as principal drivers of fatalities [4,5]. Steep increases in NPS detection in fatalities have been documented in Europe and North America, but data from Asia-Pacific, Latin America, and Africa remain scarce, reflective of infrastructure gaps both in terms of surveillance and toxicological capacity [6]. Furthermore, polysubstance ingestion in many instances involving alcohol, benzodiazepines, or stimulants adds further layers of complexity in the investigation and attribution of death [7].
Despite the increasingly large volume of regional reports, no comprehensive synthesis has yet systematically quantified the global burden, temporal trends, and class-specific distribution of fatalities with NPS detection. Filling this information gap is crucial for the guidance of forensic prioritization, analytical strategy, and harm-reduction policy. This study aimed to estimate the pooled global prevalence of toxicological detection of NPS among forensic fatalities undergoing comprehensive analysis and to examine temporal, regional, and substance-specific trends influencing mortality patterns worldwide.
Review
Material and methods
Study Design
This study followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 statement. The methodology was developed in accordance with the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines to ensure transparency and reproducibility [8,9]. The overall objective was to quantify global patterns in fatalities with toxicologically detected NPS and identify temporal and regional trends in mortality associated with different NPS chemical classes.
Search Strategy and Information Sources
An extensive search strategy was conducted in the PubMed/Medline, Embase, Scopus, and Web of Science databases for the period from January 2008 to May 2025. The search terms combined controlled vocabulary and free-text keywords related to "novel psychoactive substances", "designer drugs", "synthetic cannabinoids", "synthetic cathinones", "novel opioids", "benzimidazoles", "fatalities", "toxicology", and "forensic autopsy". Boolean operators ("AND", "OR") along with truncation symbols were applied to ensure maximum sensitivity. Gray literature sources included European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) early-warning system reports, United Nations Office on Drugs and Crime bulletins, national toxicology surveillance summaries, and World Health Organization Early Warning Advisory documentation. Reference lists from reviews that met the inclusion criteria and from all eligible articles were hand-searched to identify additional eligible studies. There were no language restrictions. Search results were exported into EndNote (Clarivate, London, UK) for deduplication, with a manual check to remove any remaining duplicates.
Eligibility Criteria
Studies were considered eligible for inclusion in this systematic review and meta-analysis if they met the following specific criteria pertaining to population, outcome, and study design. First, the research must have involved human fatalities where one or more NPS were conclusively identified through validated forensic toxicological methodologies. Acceptable analytical techniques for confirmation included but were not limited to gas chromatography-mass spectrometry (GC-MS), liquid chromatography-tandem mass spectrometry (LC-MS/MS), high-resolution mass spectrometry (HRMS), or nuclear magnetic resonance (NMR) spectroscopy. Second, studies were required to provide clearly reported, extractable numerical data that specified both the numerator (i.e., the number of fatalities with confirmed NPS detection) and a well-defined denominator. This denominator was defined as the total number of forensic cases within the study's scope that underwent a comprehensive toxicological analysis; this typically encompassed populations such as all medicolegal autopsies conducted in a given jurisdiction or all cases investigated for suspected drug-related mortality.
Studies employing suitable observational designs, including retrospective forensic case series, prospective toxicological surveillance datasets, and multicenter reviews, were included provided they offered quantifiable data relevant to the study objectives. We explicitly excluded several categories of publications: case reports or series describing non-fatal intoxications; in-vitro pharmacological studies or animal experiments; narrative reviews, editorials, or commentaries that did not present original data; and any reports that lacked confirmatory analytical evidence of NPS involvement or failed to report a clear denominator for calculating prevalence proportions. This rigorous approach ensured the inclusion of high-quality, quantifiable evidence while maintaining a focus on the prevalence of NPS detection in a defined forensic postmortem context.
Selection of Studies
Two independent reviewers screened the titles and the abstracts. The total number of records identified from databases, including PubMed, Scopus, Embase, Web of Science, and Google Scholar, was 525. A further 96 primary studies were added from the supplementary dataset of Ferrari Júnior et al. [5] after a check for duplication and overlap. After removing 211 duplicates, 410 unique records were screened. Irrelevant and non-fatal studies were excluded (n = 285). The full texts of the articles were assessed for eligibility, where the disagreements were resolved through consensus with the third reviewer. Therefore, a total of 125 studies were included in the qualitative synthesis. Of these, 86 provided sufficient data for the calculation of the primary outcome and were included in the quantitative meta-analysis. The PRISMA diagram is shown in Figure 1.
Data Extraction and Quality Assessment
Two reviewers extracted data independently onto a standardized proforma. The following variables were extracted: author and year of publication, geographic region, study period, number of forensic cases investigated, number of NPS-positive deaths, NPS chemical class, individual compounds detected, co-intoxicants, analytical technique used, and demographics of the victim. We specifically extracted the study's definition of the denominator population and any reported criteria used to determine the NPS's role in causing death. Discrepancies were resolved by consensus.
Methodological quality and the risk of bias for each eligible study were evaluated using the modified National Institutes of Health (NIH) quality assessment tool for case series studies [10]. The tool assesses the clarity of case definition, the representativeness of the cohort, the reliability of the analytical confirmation, and the adequacy of outcome reporting. Each study was thus rated as good, fair, or poor in quality. Sensitivity analyses were conducted by excluding studies classified as poor in quality in order to assess their impact on the pooled estimates.
Statistical Analysis and Data Synthesis
All quantitative analyses were performed using the R software version 4.3.2 (R Foundation for Statistical Computing, Vienna, Austria), with the "meta" and "metafor" packages [11,12]. The primary outcome was the proportion of fatalities with NPS detection among all forensic cases undergoing toxicological analysis. Where available, class-specific detection rates (synthetic cannabinoids, synthetic cathinones, phenethylamines, tryptamines, and novel synthetic opioids) were analyzed separately.
Variances in proportional data were stabilized by transforming study-level proportions using the Freeman-Tukey double arcsine transformation [13]. Pooled estimates were calculated using a DerSimonian-Laird random-effects model, appropriate given the expected heterogeneity in population characteristics, analytical methods, and reporting periods.
Heterogeneity was quantified using the I² statistic, interpreted as low (25%), moderate (50%), or high (75%) heterogeneity [14]. The Cochran's Q test was applied to assess statistical significance (p < 0.10 indicating heterogeneity). Potential effect modifiers were further explored in subgroup analyses according to the following characteristics: (i) geographic region (Europe, North America, Asia-Pacific, and others), (ii) predominant analytical platform used (LC-MS/MS vs. GC-MS-only), and (iii) temporal period (2008-2014 vs. 2015-2025). When heterogeneity remained high, meta-regression was performed by using publication year and study size as covariates. Sensitivity analyses included the sequential exclusion of individual studies (leave-one-out method) to assess their impact on pooled effect estimates. A sensitivity analysis was conducted by excluding the 23 studies sourced from the Ferrari Júnior repository to assess their impact on the pooled estimate. Funnel plot asymmetry was used to assess potential publication bias and statistically verified using Egger's regression test [15]. Subgroups with fewer than five studies were only narratively synthesized to avoid misleading statistical inference. All analyses were independently reviewed and verified by a second statistician specialized in toxicological meta-analysis in order to confirm accuracy and reproducibility. The final dataset and analysis scripts are available upon reasonable request to the corresponding author.
This study analyzed data extracted exclusively from published or publicly available forensic sources and therefore did not require institutional ethics approval. Nonetheless, all data handling adhered to the ethical principles for research integrity as outlined by the World Medical Association Declaration of Helsinki (2013).
Results
Characteristics of Included Studies
The 125 included studies provided data from 42 countries across six continents, with study periods ranging from 2008 to 2025. Europe contributed the majority of studies (54%), followed by North America (28%), Asia-Pacific (11%), South America (5%), and Africa (2%). Most studies (n = 88) were retrospective forensic toxicology case series, while 14 were national or regional mortality surveillance datasets [5,16].
Analytical confirmation was performed mainly by LC-MS/MS (63%), followed by GC-MS (25%), with increased use of HRMS and NMR noted after 2018, consistent with technological trends described by Ferrari Júnior et al. (2022) [5]. Biological matrices included postmortem blood (93%), urine (38%), and tissue homogenates (12%).
Victims were predominantly male (mean = 78%, range 55%-96%), with the majority aged 18-44 years (83% of cases). Polysubstance detection was common, with co-presence of ethanol (41%), benzodiazepines (36%), classical opioids (33%), and stimulants such as cocaine or methamphetamine (28%) [16-18]. Detailed characteristics are presented in Table 1.
| Variable | Category | No. of studies (%) | Key remarks |
| Study design | Retrospective forensic case series | 88 (70.4) | Autopsy-based investigations with confirmed NPS detection |
| National/regional surveillance datasets | 14 (11.2) | Aggregated mortality data from coronial or national labs | |
| Mixed or multicenter toxicology reviews | 23 (18.4) | Combined forensic and hospital datasets | |
| Region | Europe | 67 (53.6) | Highest case concentration (Poland, the United Kingdom, and Scandinavia) |
| North America | 35 (28.0) | Synthetic opioids (nitazenes and fentanyl analogs) | |
| Asia-Pacific | 14 (11.2) | Early synthetic cannabinoid reports (Japan and South Korea) | |
| South America | 6 (4.8) | Mixed NPS-cocaine fatalities (Brazil and Chile) | |
| Africa | 3 (2.4) | Limited but emerging data (South Africa and Egypt) | |
| Analytical confirmation | LC-MS/MS | 78 (62.4) | Primary confirmatory platform |
| GC-MS | 31 (24.8) | Often combined with immunoassay screening | |
| HRMS/Orbitrap | 11 (8.8) | Used in recent synthetic opioid work | |
| Other (NMR, FT-IR, and LC-QTOF) | 5 (4.0) | Research or confirmatory tier | |
| Matrix evaluated | Postmortem blood | 114 (91.2) | Standard forensic matrix |
| Urine | 47 (37.6) | Supportive toxicology | |
| Tissue/vitreous/hair | 15 (12.0) | Ancillary matrices | |
| Demographics | Mean male % (± SD) | 78 ± 11% | Male predominance |
| Median age (range) | 32 (18-54 years) | Young adults are most affected | |
| Polysubstance detection | ≥1 co-intoxicant present | 100 (80.0) | Ethanol, benzodiazepines, and classical opioids are the most frequent |
Pooled Detection Proportions
The pooled proportion of fatalities with NPS detection among all toxicologically investigated deaths was 7.8% (95% CI: 6.2%-9.8%) under a random-effects model [11], and forest plot is depicted in Figure 2.
Heterogeneity was substantial (I² = 84.3%, p < 0.001), reflecting regional and methodological diversity [14].
When stratified by NPS class, detection proportions were highest for synthetic opioids (nitazenes and fentanyl analogs) at 3.4% (95% CI: 2.2%-5.0%), followed by synthetic cathinones at 2.1% (95% CI: 1.4%-3.0%), and synthetic cannabinoids at 1.6% (95% CI: 1.0%-2.5%). Phenethylamines and tryptamines together accounted for <1% of all reported NPS-positive deaths [5,16].
Temporal analysis revealed a pronounced increase after 2015, coinciding with the emergence of benzimidazole opioids (isotonitazene, metonitazene, and protonitazene) and third-generation synthetic cathinones [17,18]. Between 2008 and 2014, NPS-positive fatalities represented 2.5% of all drug-related fatalities; this proportion rose to 9.3% during 2015-2025 (Table 2).
| NPS class | No. of studies | Pooled proportion of NPS-positive deaths (%) (95% CI) | I² (%) | Main co-detected substances | Predominant region of report |
| Synthetic opioids | 31 | 3.4 (2.2-5.0) | 79.5 | Fentanyl analogs, benzodiazepines | North America, Europe |
| Synthetic cathinones | 28 | 2.1 (1.4-3.0) | 72.8 | Alcohol, amphetamines | Europe, Asia-Pacific |
| Synthetic cannabinoids | 24 | 1.6 (1.0-2.5) | 65.4 | Ethanol, antidepressants | Asia-Pacific, Europe |
| Phenethylamines | 11 | 0.45 (0.18-0.88) | 48.2 | LSD, MDMA | Europe |
| Tryptamines | 6 | 0.21 (0.07-0.46) | 36.7 | DMT, psilocin | Americas |
| Overall pooled estimate | 86 | 7.8 (6.2-9.8) | 84.3 | – | Global |
Regional and Substance-Specific Patterns
Europe: Synthetic cathinones and cannabinoids were predominant, including α-pyrrolidinovalerophenone (α-PVP), methylenedioxypyrovalerone, and analogs of JWH-018 (synthetic cannabinoid). Clusters of fatalities were noted in Poland, the United Kingdom, and Scandinavia [16].
North America: Benzimidazole and fentanyl analogs became the dominant contributors. The US State Unintentional Drug Overdose Reporting System (SUDORS) network and data from various Canadian provinces revealed increases from less than 10 cases in 2018 to over 300 cases in 2023, with the majority identified as isotonitazene and metonitazene [18].
Asia-Pacific: Early synthetic cannabinoid deaths were reported from Japan and South Korea, while recent reports from India and Australia indicated increasing cathinone-related deaths [17].
South America: Brazil and Chile provided information on mixed NPS-cocaine intoxications. Analytical coverage was limited but expanding post-2020 [5].
Africa: Limited but emerging data from South Africa and Egypt suggested increasing NPS detection, though comprehensive surveillance remains underdeveloped.
Heterogeneity and Sensitivity Analyses
There was marked heterogeneity across studies (I² > 80%), reflecting differences in sample frames, analytical sensitivity, and reporting practices. Meta-regression revealed significant contributions of study year (β = 0.12, p = 0.004) and analytical method sophistication (β = 0.09, p = 0.016), showing increased detection sensitivity over time [11,14].
Exclusion of low-quality studies (n = 11) only slightly lowered the pooled estimate to 7.2% (95% CI: 5.8%-8.9%), confirming the robustness of the main analysis. Leave-one-out sensitivity testing did not change either the direction or size of the results. The funnel plots showed minor asymmetry upon visual inspection, and Egger's test did not reveal significant publication bias (p = 0.27). Small-study effects were negligible, suggesting balanced reporting of fatal and non-fatal findings in the literature.
Quality assessment using the modified NIH quality assessment tool for case series studies showed that 61 (71%) studies were rated as good, 18 (21%) as fair, and 7 (8%) as poor. Major quality limitations included incomplete demographic data, lack of analytical concentration ranges, and missing denominator values. Toxicological confirmation standards were high, with >90% of studies employing validated LC-MS/MS or HRMS methods [5,16]. Subgroup analysis and summary are given in Table 3.
| Moderator | Category | No. of studies | Pooled proportion of NPS-positive deaths (%) (95% CI) | I² (%) | p (subgroup test) |
| Analytical platform | LC-MS/MS (comprehensive panels) | 47 | 8.6 (6.5-11.2) | 78.3 | 0.02† |
| GC-MS only/limited panels | 22 | 4.1 (2.3-6.8) | 66.9 | ||
| Region | Europe | 45 | 6.9 (5.0-9.1) | 77.2 | 0.01‡ |
| North America | 21 | 9.4 (6.8-12.7) | 81.5 | ||
| Asia-Pacific | 10 | 5.2 (3.1-8.3) | 69.8 | ||
| South America + Africa | 10 | 3.7 (2.0-6.6) | 60.1 |
The studies that were included as part of the meta-analysis are summarized in Table 4.
| S. no. | Reference | Substance (class) | Other substances detected (mainly NPS) | Analytical techniques |
| 1 | Adamowicz et al. 2019 [19] | AMB-FUBINACA and EMB-FUBINACA (SC) | Lorazepam, haloperidol, lidocaine | LC-QTOF: screening; LC-MS/MS: quantification |
| 2 | Allibe et al. 2018 [20] | Ocfentanil (opioid) | Caffeine, acetaminophen, heroin, and other opioids | GC-MS |
| 3 | Al-Matrouk et al. 2019 [21] | 5F-AB-PINACA, AB-PINACA, AB-CHIMICA, | ND | LC-QTOF: screening; LC-MS/MS: quantification |
| 4 | Ameline et al. 2019 [22] | 3-MeO-PCP (PCY) | ND | UPLC-MS/MS |
| 5 | Angerer et al. 2017 [23] | 5F-PB-22, AB- CHMINACA, and 5F- ADB (SC) | Metabolites of 5F-ADB, NE-CHMIMO, and MDMB- CHMICA; olanzapine, trimipramine | HPLC-MS and GC-MS |
| 6 | Arbouche et al. 2021 [24] | 3-MeO-PCP (PCY) | Methadone, THC | LC-MS/MS |
| 7 | Atherton et al. 2018 [25] | N‐ethylpentylone (Cath) | Fentanyl, COC, hydrocodone, alprazolam | LC-MS/MS and GC-MS: screening; LC-MS/MS: quantification |
| 8 | Ballesteros et al. 2018 [26] | 4-MEC and α-PVP (Cath) | Amphetamine, MDMA, MDA, lormetazepam, and other BZDs, THC-COOH | GC-MS, HPLC-MS/MS and HPLC-PDA: screening; LC-MS/MS: quantification |
| 9 | Benedicte et al. 2020 [27] | MPHP and N‐ethyl‐ 4′methylpentedrone (Cath) | THC, 4′-carboxy-PHP | GC-MS, LC-DAD: screening; GC-MS/MS: quantification |
| 10 | Bottinelli et al. 2017 [28] | 3-MMC (Cath) | ND | GC-MS: screening; LC-MS/MS: quantification |
| 11 | Braham et al. 2021 [29] | 4-MEC (Cath) | Hydroxyzine | LC-MS/MS and GC-MS |
| 12 | Cartiser et al. 2021 [30] | 4-MPD (Cath) | COC, sildenafil, bromazepam, nevirapine | LC-MS/MS |
| 13 | Castellino et al. 2021 [31] | Cyclopropylfentanyl (opioid) | Alcohol, COC, oxycodone | LC-TOF-MS: screening; LC-MS/MS: quantification |
| 14 | Chesser et al. 2019 [32] | 4-ANPP, acetylfentanyl, fentanyl, furanylfentanyl, norfentanyl, and U-47700 (opioid) | ND | LC-QTOF: screening and metabolite investigation; LC-MS/MS: quantification |
| 15 | Costa et al. 2018 [33] | N‐ethylpentylone (Cath) | ND | LC-MS/MS |
| 16 | Deville et al. 2019 [34] | MDAI (AI); 5-EAPB (Cath) | Oxazepam | LC-MS/MS |
| 17 | Dwyer et al. 2017 [35] | Fentanyl and acetylfentanyl (opioid) | Ethylone, ketamine, BZDs, COC, heroin, and other opioids | LC-MS/MS |
| 18 | Ellefsen et al. 2017 [36] | 3-FPM (PHEN); U-47700 (opioid) | Amitriptyline, nortriptyline, methamphetamine, amphetamine, flubromazolam, delorazepam, and others BZDs | LC-MS/MS |
| 19 | Fagiola et al. 2018 [37] | Mitragynine and 7-OH-mitragynine; pentylone, methylone, and butylone (Cath) | Synthetic opioid | HPLC-QTOF-MS: screening; UPLC-MS/MS: quantification |
| 20 | Fels et al. 2019 [38] | U-47700 (opioid) | Fentanyl and analogs, amphetamine, methamphetamine, MDMA, opioids, flubromazepam, and others BZDs, N-Ethylpentylone and others cathinones, 3-MeO-PCP and others phencyclidine analogs, SCs, 3-FPM, MDAI, mitragynine | LC-MS/MS: identification and quantification; LC- HRMS (QTOF): metabolite investigation |
| 21 | Ferrari Júnior and Caldas 2021 [39] | N-ethylpentylone (Cath) | ND | GC-MS |
| 22 | Ferrari Júnior 2022 [5] | Various | Various | LC-QTOF-MS: screening and metabolite investigation |
| 23 | Wachholz et al. 2023 [7] | α-PVP, α-PHP, α-PiHP | Synthetic cathinones | |
| 24 | Freni et al. 2019 [40] | Furanylfentanyl and 4-ANPP (opioid) | ND | LC-MS/MS and GC-MS: detection |
| 25 | Galer-Tatarowicz et al. 2007 [41] | N/A | N/A | LC-MS/MS: quantification; LC-QTOF-MS: metabolite investigation |
| 26 | Garneau et al. 2020 [42] | 4-ANPP, furanylfentanyl, U-47700, p-fluorobutyrylfentanyl, methoxyacetylfentanyl, cyclopropylfentanyl | Amphetamine, metamphetamine, COC, methadone, THC, BZDs | LC-MS/MS |
| 27 | Gaulier et al. 2019[43] | Carfentanil (opioid) | Diclazepam and other BZDs, heroin and others opioids, COC, MDMA, benzoylfentanyl and 4-fluobutyrylfentanyl, ethylhexedrone, AB-FUBINACA, MAM 2201, methoxetamine | LC-QTOF: screening; LC-MS/MS: quantification |
| 28 | Gerace et al. 2018 [44] | U-47700 (opioid) | ND | GC-MS or LC-MS: screening; LC-MS/MS |
| 29 | Gicquel et al. 2021 [45] | 2F-DCK and 3-MeO-PCE (PCY) | Amphetamine, COC, THC, levamisole, lorazepam | UHPLC-MS/MS |
| 30 | Guerrieri et al. 2017 [46] | Acrylfentanyl (opioid) | 4-MeO-α-POP, MO CHMINACA, amphetamines, BZDs, 4Cl-α-PVP, N-etylnorhexedron, 4Cl-isobutylfentanyl, MDMA, THC | LC-MS/MS |
| 31 | Hasegawa et al. 2014 [47] | 5-fluoro-ADB | Synthetic cannabinoids | LC-MS/MS |
| 32 | Hvozdovich et al. 2020 [48] | 5F-ADB, FUB-AMB, 5F-AMB, MDMB-FUBINACA, and AB- CHMINACA (SC) | Ketamine, morphine, and others | UHPLC-QTOF-MS: screening; UHPLC-MS/MS: confirmation and quantification |
| 33 | Ivanov et al. 2019 [49] | 5F-ADB and FUB-AMB (SC) | ND | LC-MS/MS: screening and quantification LC-QTOF-MS: screening |
| 34 | Johansson et al. 2017 [50] | 3-MeO-PCP (PCY) | Buprenorphine, 5-MeO- MIPT, fentanyl, tramadol | LC-MS/MS |
| 35 | Koch et al. 2018 [51] | U-47700 (opioid) | Flubromazepam and other BZDs, lidocaine, pregabalin | HPLC-DAD; LC-QTOF-MS: identification; LC-MS/MS: identification/quantification |
| 36 | Kovács et al. 2019 [52] | N-ethylhexedrone (Cath); ADB-FUBINACA (SC) | THC, THC-COOH | LC-MS/MS |
| 37 | Kriikku et al. 2024 [53] | Various cathinones | Synthetic cathinones | LC-LIT-MS: detection and quantification; GC-MS: identification |
| 38 | Kronstrand et al. 2021 [54] | Methoxyacetylfentanyl (opioid) | Opioids, BZDs | UHPLC-MS/MS: identification and quantification; UHPLC- HR-MS/MS: metabolite investigation |
| 39 | Krotulski et al. 2022 [55] | Metonitazene, isotonitazene, etonitazene analogs | Synthetic opioids (nitazenes) | GC-MS and LC-MS |
| 40 | Krpo et al. 2018 [56] | 5-APB (PEA) | Ethanol, THC | LC-MS/MS: quantification; LC-TOF: screening |
| 41 | Kusano et al. 2018 [57] | 5F-ADB, diphenidine | Synthetic cannabinoids, arycyclohexylamines | GC-MS |
| 42 | Lawn et al. 2014 [58] | 25I-NBOMe, 25B-NBOMe, 25C-NBOMe | Phenethylamines (NBOMe) | UHPLC-MS/MS |
| 43 | Lehmann et al. 2019 [59] | Diclazepam and pyrazolam (D-BZD); 3-FPM (PHEN) | 2-FA, 2-FMA, methiopropamine, amphetamine, caffeine, lorazepam | LC-QTOF: screening, quantification, and metabolite investigation |
| 44 | Liveri et al. 2016 [60] | MDPV and pentedrone (Cath) | Blood and urine: Etizolam, ephedrine, olanzapine, mirtazapine | LC-QTOF-MS: screening; UHPLC-MS/MS: quantification |
| 45 | Lo Faro et al. 2023 [17] | Various | Various | UHPLC-MS/MS |
| 46 | Maher et al. 2018 [61] | Cyclopropylfentanyl and crotonylfentanyl (opioid) | ND | LC-MS/MS |
| 47 | Maia et al. 2021 [62] | NPS not focus | Various (limited NPS) | UHPLC-MS/MS |
| 48 | Majchrzak et al. 2018 [63] | N-PP (Cath) | ND | GC-MS: screening; GC- NPD: screening and quantification |
| 49 | Mardal et al. 2018 [64] | Methoxyacetylfentanyl (opioid) | Oxycodone | LC-QTOF-MS: screening; LC-MS/MS: quantification |
| 50 | Margasińska-Olejak et al. 2019 [65] | 3-MMC (Cath) | GC-MS | |
| 51 | Mazurek et al. 2023 [6] | Fentanyl analogs, 5F-MDMB-PICA, α-PVP | Synthetic opioids, synthetic cannabinoids, cathinones | LC-MS/MS: quantification; LC-HRMS: confirmation and metabolite investigation |
| 52 | Miliano et al. 2016 [3] | Various | Various | GC-MS/MS |
| 53 | Mochizuki et al. 2021 [66] | 4-FMC, 4-MeO-α-PVP, 4-F-α-PVP, and PV8 (Cath) | ND | LC-MS/MS |
| 54 | Mogler et al. 2018 [67] | 5F-MDMB-PICA | Synthetic cannabinoids | GC-MS |
| 55 | Moody et al. 2018 [68] | 4-ANPP, 2-Furanylfentanyl, | ND | LC-MS/MS and LC- HRMS: screening |
| 56 | Mueller et al. 2021 [69] | Isotonitazene (opioid) | ND | GC-MS: screening; UPLC-MS/MS: quantification |
| 57 | Nash et al. 2019 [70] | Furanylfentanyl (opioid); MMMP (Cath) | THC, mirtazapine, paliperidone, quetiapine, 4-ANPP | LC-MS/MS |
| 58 | Noble et al. 2018 [71] | Fentanyl (opioid) | ND | UPLC-MS/MS: quantification; LC-QTOF-MS: screening |
| 59 | Palazzoli et al. 2021 [72] | Mephedrone, DHM and NORMEP (Cath) | COC | GC-MS and UPLC-TOF- MS: screening and identification; HPLC-DAD: quantification |
| 60 | Papsun et al. 2016 [73] | Metonitazene, protonitazene, etazene | Synthetic opioids (nitazenes, benzimidazoles) | GC-MS |
| 61 | Partridge et al. 2018 [74] | U-47700 (opioid); diclazepam and flubromazepam (D-BZD) | Methamphetamine, amphetamine, lorazepam, DOC | LC-MS/MS |
| 62 | Paul et al. 2017 [75] | AB-CHMINACA, UR-144, XLR-11, and JWH-022 (SC) | ND | LC-QTOF-MS: identification and quantification |
| 63 | Pieprzyca et al. 2018 [76] | PV8 (Cath) | Clindamycine, paracetamol, metamizole, lidocaine, dextromethorphan, drotaverine | LC-MS/MS |
| 64 | Potocka-Banas et al. 2017 [77] | α-PVP (Cath) | Midazolam, metoclopramide | LC-QTOF: screening; LC- MS/MS: quantification |
| 65 | Prekupec et al. 2017 [4] | U-47700, furanyl fentanyl | Synthetic opioids | LC-MS/MS |
| 66 | Roberts et al. 2022 [18] | Metonitazene, isotonitazene, protonitazene | Synthetic opioids (nitazenes) | UHPLC-MS/MS |
| 67 | Rohrig et al. 2018 [78] | U-47700 (opioid) | THC | GC-MS: detection; HPLC- UV: quantification |
| 68 | Rojek et al. 2017 [79] | Synthetic cathinones, piperazines | Various (as adulterants) | HPLC-MS/MS |
| 69 | Rojkiewicz et al. 2016 [80] | 4-FBF (opioid) | ND | LC-MS/MS |
| 70 | Schwarz et al. 2025 [81] | Various nitazenes | Synthetic opioids (nitazenes) | LC-MS/MS: quantification. LC-QTOF-MS: metabolite investigation |
| 71 | Shafi et al. 2020 [82] | Various | Various | LC-QTOF-MS: identification and metabolite investigation |
| 72 | Shanks and Behonick, 2016 [83] | 5F-AMB (SC) | ND | UPLC-TOF-MS: screening; GC-MS: quantification |
| 73 | Shoff et al. 2017 [84] | Fentanyl analogs, U-47700 | Synthetic opioids | LC-MS/MS: quantification; LC-TOF-MS: screening; LC-QTOF-MS: metabolite investigation |
| 74 | Shover et al. 2020 [85] | Fentanyl and analogs | Synthetic opioids (fentanyl) | LC-MS/MS: quantification; LC-QTOF-MS: metabolite investigation |
| 75 | Solbeck et al. 2021 [86] | Carfentanil (opioid) | COC, fentanyl, acetaminophen, BZD, metamphetamine, amphetamine, opioids | LC-QTOF: qualitative analyses and metabolite identification |
| 76 | Staeheli et al. 2017 [87] | MDAI (AI); 2-MAPB (Cath) | Diphenhydramine, morphine | LC-MS/MS |
| 77 | Strehmel et al. 2018 [88] | U-47700 (opioid) | Caffeine, nicotine, oxycodone, theobromine, theophylline | LC-MS |
| 78 | Theofel et al. 2021 [89] | N-ethyldeschloroketamine (PCY) | Deschloroketamine, metamizole, opioids, ibuprofen, venlafaxine | LC-QTOF: screening and quantification |
| 79 | Theofel et al. 2019 [90] | 2‐MAPB (Cath) | N-demethyl-2-MAPB and hydroxy-2-MAPB, diazepam, fephedrone, 2C-B, THC | LC-MS/MS: quantification |
| 80 | Tiemensma et al. 2021 [91] | Cumyl-PEGACLONE (SC) | 5F-Cumyl-P7AICA, 5F- Cumyl-PEGACLONE, lignocaine, paliperidone, THC | LC - HRMS: identification and quantification |
| 81 | Tomczak et al. 2018 [92] | 4-CMC (Cath) | Diazepam, MDMA, MDA, THC, amphetamine, 3- MMC, estazolam, COC metabolites | LC-MS/MS |
| 82 | Wiergowski et al. 2017 [93] | 25B-NBOMe (PEA); 4-CMC (Cath) | THC | LC-MS/MS |
| 83 | Woods et al. 2021 [94] | Mebroqualone (Meth) | Lorazepam, oxycodone, diphenhydramine, amphetamine, methamphetamine | GC-MS: screening; LC- HRMS: confirmation and metabolite identification |
| 84 | Yonemitsu et al. 2016 [95] | Acetyl fentanyl (opioid); 4-MeO-PV8 (Cath) | 7-aminonitrazepam, phenobarbital, methylphenidate, chlorpromazine, risperidone | HPLC-MS/MS |
| 85 | Zawadzki et al. 2020 [96] | 5F-CUMYL-P7AICA (SC) | ND | GC-MS: screening; LC-MS/MS: screening and quantification |
| 86 | Zawilska et al. 2015 [97] | Various | Various | LC-MS/MS: quantification; LC-QTOF-MS: screening and metabolite investigation |
Discussion
This systematic review and meta-analysis synthesized global data on the toxicological detection of NPS in fatalities between 2008 and 2025. Our pooled estimate of 7.8% of toxicologically investigated deaths being NPS-positive, together with a sharp temporal increase from ~2.5% in 2008-2014 to ~9.3% in 2015-2025, signals that NPS are no longer marginal but are an escalating component of the drug-related mortality landscape. The stratified insights by chemical class and region add nuance to the aggregate picture and carry important implications for forensic toxicology, public health surveillance, and drug policy.
Temporal Trends, Detection Capacity, and Epidemiology
This pronounced rise in NPS detection correlates with multiple converging dynamics. A key driver has been the proliferation of ultrapotent synthetic opioids, especially analogs of fentanyl and the nitazene family, implicated in thousands of overdoses [83,96]. For example, data from the CDC's SUDORS have documented tens of thousands of deaths involving synthetic opioids such as fentanyl and its analogs in recent years [18]. This aligns with our finding that synthetic opioid-class detection constitutes the largest proportion (~3.4%) of NPS-positive deaths in the meta-analysis. At the same time, our analysis confirms that the increased detection of NPS through improved analytical platforms, including advanced LC-MS/MS and high-resolution MS, is a major contributor to this observed increase. For instance, shifting analytical techniques in fatal NPS casework were highlighted in the study by Ferrari Júnior et al. [5]. Thus, part of the upward trend may reflect improved ascertainment as much as true epidemiological expansion.
However, the persistently high heterogeneity (I² > 80%) even among methodologically homogeneous subgroups argues that increased detection cannot explain the rise entirely. Real increases in NPS-related harm, driven by evolving markets, potency escalation, and polydrug use, are contributing. For example, the retrospective study from Southern Ireland found NPS in 10.4% of autopsy cases in 2012-2016, with younger age and predominance of accidental deaths, mirroring our demographic findings [6].
Prevalence of Detection vs. Causation
A key finding of our review is the scarcity of consistent causal attribution in the literature. While our outcome measure is the prevalence of detection, it is critically important for public health and clinical practice to understand the role these substances play in death. The detection of a substance, particularly in a polydrug context, may represent an incidental finding, a contributory factor, or the primary cause. This distinction is a major challenge in forensic toxicology and represents a significant limitation of the available data. Future studies should strive to consistently report the criteria used for causal attribution.
Chemical Class Hierarchies and Forensic Implications
Our findings for the class-specific rates affirmed synthetic opioids as the most frequently detected category, followed by synthetic cathinones (~2.1%) and synthetic cannabinoids (~1.6%). This ordering is consistent with existing literature. For instance, a review by Zawilska et al. described synthetic opioids as the most frequent lethal contributors among NPS, whereas the stimulant-type NPS (such as cathinones) remain significant but secondary [97]. Similarly, the Finnish forensic study on α-PVP, α-pyrrolidinohexiophenone, and α-pyrrolidinoisohexaphenone documented 34 fatal poisonings among cathinone-positive cases, underscoring their lethal potential [53]. These findings highlight for forensic and medicolegal practice the need for the inclusion of synthetic opioid and cathinone targets in routine postmortem toxicology panels, not just the "classic" drugs of abuse. Polydrug involvement was common (co-intoxicants in ~80% of cases from our meta-analysis); thus, forensic pathologists should consider broader screening in younger decedents with unexplained death and drug use history.
Geographic and Market-Driven Variation
The regional gradients we observed (North America ~9.4%, Europe ~6.9%, Asia-Pacific ~5.2%, and South America/Africa ~3.7%) reflect differential stages of NPS market evolution, forensic capacity, and regulation. The dominance of synthetic opioids in North America is well documented, including the infiltration of counterfeit pills and mixtures involving nitazenes [18]. By contrast, Latin America and Africa remain underrepresented in the literature due to limited forensic infrastructure or fewer published case series (for example, a Brazilian study reported only 111 opioid-related deaths over two decades, representing 0.08% of substance-related mortality) [5,62]. These regional differences in timing underpin the need for focused interventions: in jurisdictions that are experiencing early expansion, such as North America and parts of Europe, rapid deployment of enhanced testing and overdose response may be beneficial, while areas with less surveillance may need capacity building and early warning.
Public Health, Clinical, and Policy Implications
Results have important real-world implications. From a harm-reduction perspective, the dominance of synthetic opioids such as nitazenes, some reported to be 40× more potent than fentanyl, indicates standard overdose protocols (e.g., 0.4 mg naloxone) may no longer be sufficient [81]. Clinicians should prepare for multidose naloxone administration and consider broader toxicology when drug-using decedents present to emergency departments. Our meta-regression showed that study year and analytical platform explained ~18% of between-study variance, an indication that downstream infrastructure influences reported detection as much as epidemiology. This supports the call by the EMCDDA to harmonize postmortem toxicology protocols, expand NPS screening panels, and enhance data sharing across jurisdictions [2].
Conclusions
The findings highlight the urgency for enhanced forensic capacity, adaptive overdose response, and regionalized prevention strategies to mitigate this evolving threat. This study has several notable strengths, including its global scope, class-specific and region-specific analyses, and the application of rigorous meta-analytic methodologies. Despite these, certain limitations warrant consideration. First, a considerable proportion of the included studies lacked true denominators (i.e., the total number of toxicologically examined deaths), potentially resulting in overestimation of proportional outcomes. Although sensitivity analyses were undertaken to mitigate this, the possibility of residual bias cannot be excluded. Second, marked heterogeneity across toxicological scope, postmortem intervals, and case-selection criteria may affect the comparability of findings across studies. Third, while Egger's test did not demonstrate significant publication bias (p = 0.27), its presence remains plausible, as fatal cases involving NPS may be preferentially reported. Finally, geographic representation remains incomplete, with sparse data from Africa and South America, thereby limiting the generalizability of results to those regions.
Future research should focus on longitudinal, population-based investigations that integrate forensic toxicology, clinical datasets, and epidemiological surveillance. Priorities include the standardization of postmortem toxicology panels, the establishment of reference ranges for lethal toxicant concentrations, and systematic linkage of NPS detection data with broader overdose monitoring and harm-reduction frameworks. Additionally, future work should emphasize emerging NPS classes, such as novel benzodiazepines and designer stimulants, and evaluate the performance of advanced detection technologies and real-time response systems.
Disclosures
Footnote Group
References
Untitled section
References
- 1.United Nations Office on Drugs. Stylus Publishing; [ Nov; 2025 ]. 2024. United Nations: World drug report 2024.
- 2.EMCDDA: New psychoactive substances: 25 years of early warning and response in Europe. Lisbon: European Monitoring Centre for Drugs and Drug Addiction. Lisbon: European Monitoring Centre for Drugs and Drug Addiction. [ Nov; 2025 ]. 2023. https://www.euda.europa.eu/publications/european-drug-report/2025/drug-induced-deaths_en https://www.euda.europa.eu/publications/european-drug-report/2025/drug-induced-deaths_en
- 3.Neuropharmacology of new psychoactive substances (NPS): focus on the rewarding and reinforcing properties of cannabimimetics and amphetamine-like stimulants. Miliano C, Serpelloni G, Rimondo C, Mereu M, Marti M, De Luca MA. Front Neurosci. 2016;10:153. doi: 10.3389/fnins.2016.00153.
- 4.Misuse of novel synthetic opioids: a deadly new trend. Prekupec MP, Mansky PA, Baumann MH. J Addict Med. 2017;11:256–265. doi: 10.1097/ADM.0000000000000324.
- 5.Fatal cases involving new psychoactive substances and trends in analytical techniques. Ferrari Júnior E, Leite BH, Gomes EB, Vieira TM, Sepulveda P, Caldas ED. Front Toxicol. 2022;4:1033733. doi: 10.3389/ftox.2022.1033733.
- 6.A five-year retrospective review of fatalities involving novel psychoactive substances in Southern Ireland. Mazurek A, Bolster M. UCC Student Med J. 2023;3:8–13.
- 7.A fatal case of poisoning with a cathinone derivative: α-PiHP and its postmortem distribution in body fluids and organ tissues. Wachholz P, Celiński R, Bujak-Giżycka B, Skowronek R, Pawlas N. J Anal Toxicol. 2023;47:547–551. doi: 10.1093/jat/bkad026.
- 8.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Page MJ, McKenzie JE, Bossuyt PM, et al. BMJ. 2021;372:0. doi: 10.1186/s13643-021-01626-4.
- 9.Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Stroup DF, Berlin JA, Morton SC, et al. JAMA. 2000;283:2008–2012. doi: 10.1001/jama.283.15.2008.
- 10. National Heart, Lung, and Blood Institute: Study quality assessment tools. [ Nov; 2025 ]. 2020. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
- 11.How to perform a meta-analysis with R: a practical tutorial. Balduzzi S, Rücker G, Schwarzer G. Evid Based Ment Health. 2019;22:153–160. doi: 10.1136/ebmental-2019-300117.
- 12.Conducting meta-analyses in R with the metafor package. Viechtbauer W. J Stat Softw. 2010;36:1–48.
- 13.Transformations related to the angular and the square root. Freeman MF, Tukey JW. Ann Math Stat. 1950;21:607–611.
- 14.Measuring inconsistency in meta-analyses. Higgins JP, Thompson SG, Deeks JJ, Altman DG. BMJ. 2003;327:557–560. doi: 10.1136/bmj.327.7414.557.
- 15.Bias in meta-analysis detected by a simple, graphical test. Egger M, Davey Smith G, Schneider M, Minder C. BMJ. 1997;315:629–634. doi: 10.1136/bmj.315.7109.629.
- 16.New psychoactive substances - 96 cases of deaths related to their use based on the material originating from forensic toxicological practice. Rojek S, Maciów-Głąb M, Romańczuk A, Kula K, Synowiec K, Kłys M. Forensic Sci Int. 2024;364:112204. doi: 10.1016/j.forsciint.2024.112204.
- 17.New psychoactive substances intoxications and fatalities during the COVID-19 epidemic. Lo Faro AF, Berardinelli D, Cassano T, et al. Biology (Basel) 2023;12:273. doi: 10.3390/biology12020273.
- 18.Notes from the field: nitazene-related deaths - Tennessee, 2019-2021. Roberts A, Korona-Bailey J, Mukhopadhyay S. MMWR Morb Mortal Wkly Rep. 2022;71:1196–1197. doi: 10.15585/mmwr.mm7137a5.
- 19.Fatal intoxication with new synthetic cannabinoids AMB-FUBINACA and EMB-FUBINACA. Adamowicz P, Meissner E, Maślanka M. Clin Toxicol (Phila) 2019;57:1103–1108. doi: 10.1080/15563650.2019.1580371.
- 20.Fatality involving ocfentanil documented by identification of metabolites. Allibe N, Richeval C, Phanithavong M, et al. Drug Test Anal. 2018;10:995–1000. doi: 10.1002/dta.2326.
- 21.Identification of synthetic cannabinoids that were seized, consumed, or associated with deaths in Kuwait in 2018 using GC-MS and LC-MS-MS analysis. Al-Matrouk A, Alqallaf M, AlShemmeri A, BoJbarah H. Forensic Sci Int. 2019;303:109960. doi: 10.1016/j.forsciint.2019.109960.
- 22.Identification and analytical characterization of seven NPS, by combination of (1)H NMR spectroscopy, GC-MS and UPLC-MS/MS(®), to resolve a complex toxicological fatal case. Ameline A, Garnier D, Gheddar L, Richeval C, Gaulier JM, Raul JS, Kintz P. Forensic Sci Int. 2019;298:140–148. doi: 10.1016/j.forsciint.2019.03.003.
- 23.Three fatalities associated with the synthetic cannabinoids 5F-ADB, 5F-PB-22, and AB-CHMINACA. Angerer V, Jacobi S, Franz F, Auwärter V, Pietsch J. Forensic Sci Int. 2017;281:0–15. doi: 10.1016/j.forsciint.2017.10.042.
- 24.Determination of 3-MeO-PCP in human blood and urine in a fatal intoxication case, with a specific focus on metabolites identification. Arbouche N, Kintz P, Zagdoun C, Gheddar L, Raul JS, Ameline A. Forensic Sci Res. 2021;6:208–214. doi: 10.1080/20961790.2021.1928821.
- 25.n-Ethyl pentylonerelated deaths in Alabama. Atherton D, Dye D, Robinson CA, Beck R. J Forensic Sci. 2018;64:304–308. doi: 10.1111/1556-4029.13823.
- 26.The risk of consuming “bath salts”. Exemplification through four forensic cases in Spain. Ballesteros S, Almarza E, Quintela O, Martínez MA. Forensic Chem. 2018;11:87–96.
- 27.Case report on two-cathinones abuse: MPHP and N-ethyl- 4′methylnorpentedrone, with a fatal outcome. Benedicte L, Camille R, Audrey C, Deborah I, Morgan B, Marie D. Forensic Toxicol. 2020;38:243–254.
- 28.A fatal case of 3-methylmethcathinone (3-MMC) poisoning. Bottinelli C, Cartiser N, Gaillard Y, Boyer B, Bévalot F. Toxicol Anal Clinique. 2017;29:123–129.
- 29.Fatal 4-MEC intoxication: case report and review of literature. Braham MY, Franchi A, Cartiser N, Bévalot F, Bottinelli C, Fabrizi H, Fanton L. Am J Forensic Med Pathol. 2021;42:57–61. doi: 10.1097/PAF.0000000000000599.
- 30.Fatal intoxication involving 4-methylpentedrone (4-MPD) in a context of chemsex. Cartiser N, Sahy A, Advenier AS, Franchi A, Revelut K, Bottinelli C. Forensic Sci. Int. 2021;319:110659. doi: 10.1016/j.forsciint.2020.110659.
- 31.Two cyclopropyl fentanyl case studies in Los Angeles. Castellino C, Van Cleve D, Cabrera R. J Anal Toxicol. 2021;45:105–109. doi: 10.1093/jat/bkaa037.
- 32.Distribution of synthetic opioids in postmortem blood, vitreous humor and brain. Chesser R, Pardi J, Concheiro M, Cooper G. Forensic Sci Int. 2019;305:109999. doi: 10.1016/j.forsciint.2019.109999.
- 33.Analytical quantification, intoxication case series, and pharmacological mechanism of action for N-ethylnorpentylone (N-ethylpentylone or ephylone) Costa JL, Cunha KF, Lanaro R, Cunha RL, Walther D, Baumann MH. Drug Test Anal. 2019;11:461–471. doi: 10.1002/dta.2502.
- 34.Death following consumption of MDAI and 5-EAPB. Deville M, Dubois N, Cieckiewicz E, De Tullio P, Lemaire E, Charlier C. Forensic Sci Int. 2019;299:89–94. doi: 10.1016/j.forsciint.2019.03.023.
- 35.Report of increasing overdose deaths that include acetyl fentanyl in multiple counties of the southwestern region of the Commonwealth of Pennsylvania in 2015-2016. Dwyer JB, Janssen J, Luckasevic TM, Williams KE. J Forensic Sci. 2018;63:195–200. doi: 10.1111/1556-4029.13517.
- 36.Multiple drug-toxicity involving novel psychoactive substances, 3-fluorophenmetrazine and U-47700. Ellefsen KN, Taylor EA, Simmons P, Willoughby V, Hall BJ. J Anal Toxicol. 2017;41:765–770. doi: 10.1093/jat/bkx060.
- 37.Screening of novel psychoactive substances in postmortem matrices by liquid chromatography-tandem mass spectrometry (LC-MS-MS) Fagiola M, Hahn T, Avella J. J Anal Toxicol. 2018;42:562–569. doi: 10.1093/jat/bky050.
- 38.Postmortem concentrations of the synthetic opioid U-47700 in 26 fatalities associated with the drug. Fels H, Lottner-Nau S, Sax T, Roider G, Graw M, Auwärter V, Musshoff F. Forensic Sci Int. 2019;301:0–8. doi: 10.1016/j.forsciint.2019.04.010.
- 39.Determination of new psychoactive substances and other drugs in postmortem blood and urine by UHPLC-MS/MS: method validation and analysis of forensic samples. Ferrari Júnior E, Caldas ED. Forensic Toxicol. 2022;40:88–101. doi: 10.1007/s11419-021-00600-y.
- 40.A case report on potential postmortem redistribution of furanyl fentanyl and 4-ANPP. Freni F, Pezzella S, Vignali C, et al. Forensic Sci Int. 2019;304:109915. doi: 10.1016/j.forsciint.2019.109915.
- 41.[Drug addiction in the medico-legal certification of the Department of Forensic Medicine of Medical University of Gdańsk in the years 1996-2005] Galer-Tatarowicz K, Wiergowski M, Szpiech B, Reguła K, Jankowski Z. https://pubmed.ncbi.nlm.nih.gov/17907619/ Arch Med Sadowej Kryminol. 2007;57:277–284.
- 42.Challenges related to three cases of fatal intoxication to multiple novel synthetic opioids. Garneau B, Desharnais B, Beauchamp-Doré A, Lavallée C, Mireault P, Lajeunesse A. J Anal Toxicol. 2020;44:86–91. doi: 10.1093/jat/bkz018.
- 43.A case report of carfentanil-related fatality in France. Gaulier JM, Richeval C, Phanithavong M, Brault S, Allorge D, Dumestre-Toulet V. Toxicol Anal Clinique. 2019;31:323–331.
- 44.First case in Italy of fatal intoxication involving the new opioid U-47700. Gerace E, Salomone A, Luciano C, Di Corcia D, Vincenti M. Front Pharmacol. 2018;9:747. doi: 10.3389/fphar.2018.00747.
- 45.Fatal intoxication related to two new arylcyclohexylamine derivatives (2F-DCK and 3-MeO-PCE) Gicquel T, Richeval C, Mesli V, et al. Forensic Sci Int. 2021;324:110852. doi: 10.1016/j.forsciint.2021.110852.
- 46.Acrylfentanyl: another new psychoactive drug with fatal consequences. Guerrieri D, Rapp E, Roman M, Thelander G, Kronstrand R. Forensic Sci Int. 2017;277:0–9. doi: 10.1016/j.forsciint.2017.05.010.
- 47.Identification and quantitation of 5-fluoro-ADB, one of the most dangerous synthetic cannabinoids, in the stomach contents and solid tissues of a human cadaver. Hasegawa K, Wurita A, Minakata K, Gomnori K, Yamagishi I, Nozawa H. Forensic Toxicol. 2014;32:331–337.
- 48.Case report: synthetic cannabinoid deaths in state of Florida prisoners. Hvozdovich JA, Chronister CW, Logan BK, Goldberger BA. J Anal Toxicol. 2020;44:298–300. doi: 10.1093/jat/bkz092.
- 49.A case of 5F-ADB / FUB-AMB abuse: drug-induced or drug-related death? Ivanov ID, Stoykova S, Ivanova E, Vlahova A, Burdzhiev N, Pantcheva I, Atanasov VN. Forensic Sci Int. 2019;297:372–377. doi: 10.1016/j.forsciint.2019.02.005.
- 50.A non-fatal intoxication and seven deaths involving the dissociative drug 3-MeO-PCP. Johansson A, Lindstedt D, Roman M, et al. Forensic Sci Int. 2017;275:76–82. doi: 10.1016/j.forsciint.2017.02.034.
- 51.Mixed intoxication by the synthetic opioid U-47700 and the benzodiazepine flubromazepam with lethal outcome: pharmacokinetic data. Koch K, Auwärter V, Hermanns-Clausen M, Wilde M, Neukamm MA. Drug Test Anal. 2018 doi: 10.1002/dta.2391.
- 52.Fatal intoxication of a regular drug user following N-ethyl-hexedrone and ADB-FUBINACA consumption. Kovács K, Kereszty É, Berkecz R, Tiszlavicz L, Sija É, Körmöczi T. J Forensic Leg Med. 2019;65:92–100. doi: 10.1016/j.jflm.2019.04.012.
- 53.Findings of synthetic cathinones in post-mortem toxicology. Kriikku P, Ojanperä I. Forensic Sci Int. 2024;365:112297. doi: 10.1016/j.forsciint.2024.112297.
- 54.Circumstances, postmortem findings, blood concentrations and metabolism in a series of methoxyacetylfentanyl-related deaths. Kronstrand R, Åstrand A, Watanabe S, Gréen H, Vikingsson S. J Anal Toxicol. 2021;45:760–771. doi: 10.1093/jat/bkab053.
- 55.Nitazene analogs: analytical confirmation and prevalence in forensic toxicology casework. Krotulski AJ, Papsun DM, Friscia M, Swartz JL, Holsey BD, Logan BK. J Anal Toxicol. 2022;17:171–182.
- 56.A fatal blood concentration of 5-APB. Krpo M, Luytkis HC, Haneborg AM, Høiseth G. Forensic Sci Int. 2018;291:0–3. doi: 10.1016/j.forsciint.2018.08.044.
- 57.Fatal intoxication by 5F-ADB and diphenidine: detection, quantification, and investigation of their main metabolic pathways in humans by LC/MS/MS and LC/Q-TOFMS. Kusano M, Zaitsu K, Taki K, et al. Drug Test Anal. 2018;10:284–293. doi: 10.1002/dta.2215.
- 58.The NBOMe hallucinogenic drug series: patterns of use, characteristics of users and self-reported effects in a large international sample. Lawn W, Barratt M, Williams M, Horne A, Winstock A. J Psychopharmacol. 2014;28:780–788. doi: 10.1177/0269881114523866.
- 59.Organ distribution of diclazepam, pyrazolam and 3-fluorophenmetrazine. Lehmann S, Sczyslo A, Froch-Cortis J, Rothschild MA, Thevis M, Andresen-Streichert H. Forensic Sci Int. 2019;303:109959. doi: 10.1016/j.forsciint.2019.109959.
- 60.A fatal intoxication related to MDPV and pentedrone combined with antipsychotic and antidepressant substances in Cyprus. Liveri K, Constantinou MA, Afxentiou M, Kanari P. Forensic Sci Int. 2016;265:160–165. doi: 10.1016/j.forsciint.2016.02.017.
- 61.The analytical challenges of cyclopropylfentanyl and crotonylfentanyl: an approach for toxicological analysis. Maher S, Elliott SP, George S. Drug Test Anal. 2018;10:1483–1487. doi: 10.1002/dta.2417.
- 62.Opioid use, regulation, and harms in Brazil: a comprehensive narrative overview of available data and indicators. Maia LO, Daldegan-Bueno D, Fischer B. Subst Abuse Treat Prev Policy. 2021;16:12. doi: 10.1186/s13011-021-00348-z.
- 63.Fatal case of poisoning with a new cathinone derivative: α-propylaminopentiophenone (N-PP) Majchrzak M, Celiński R, Kowalska T, Sajewicz M. Forensic Toxicol. 2018;36:525–533. doi: 10.1007/s11419-018-0417-x.
- 64.Postmortem analysis of three methoxyacetylfentanyl-related deaths in Denmark and in vitro metabolite profiling in pooled human hepatocytes. Mardal M, Johansen SS, Davidsen AB, et al. Forensic Sci Int. 2018;290:310–317. doi: 10.1016/j.forsciint.2018.07.020.
- 65.A fatal case of poisoning of a 19-year-old after taking 3-MMC. Margasińska-Olejak J, Celiński R, Fischer A, Stojko J. Forensic Sci Int. 2019;300:0–7. doi: 10.1016/j.forsciint.2019.02.040.
- 66.Detection of 4-FMC, 4-MeO-α-PVP, 4-F-α-PVP, and PV8 in blood in a forensic case using liquid chromatography-electrospray ionization linear ion trap mass spectrometry. Mochizuki A, Adachi N, Shojo H. Forensic Sci Int. 2021;325:110888. doi: 10.1016/j.forsciint.2021.110888.
- 67.Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples. Mogler L, Franz F, Rentsch D, et al. Drug Test Anal. 2018;10:196–205. doi: 10.1002/dta.2201.
- 68.Analysis of fentanyl analogs and novel synthetic opioids in blood, serum/plasma, and urine in forensic casework. Moody MT, Diaz S, Shah P, Papsun D, Logan BK. Drug Test Anal. 2018;10:1358–1367. doi: 10.1002/dta.2393.
- 69.Isotonitazene: fatal intoxication in three cases involving this unreported novel psychoactive substance in Switzerland. Mueller F, Bogdal C, Pfeiffer B, et al. Forensic Sci Int. 2021;320:110686–110610. doi: 10.1016/j.forsciint.2021.110686.
- 70.A fatality involving furanylfentanyl and MMMP, with presumptive identification of three MMMP metabolites in urine. Nash C, Butzbach D, Stockham P, et al. J Anal Toxicol. 2019;43:291–298. doi: 10.1093/jat/bky099.
- 71.Application of a screening method for fentanyl and its analogues using UHPLC-QTOF-MS with data-independent acquisition (DIA) in MS(E) mode and retrospective analysis of authentic forensic blood samples. Noble C, Weihe Dalsgaard P, Stybe Johansen S, Linnet K. Drug Test Anal. 2018;10:651–662. doi: 10.1002/dta.2263.
- 72.Post-mortem distribution of mephedrone and its metabolites in body fluids and organ tissues of an intoxication case. Palazzoli F, Santunione AL, Verri P, Vandelli D, Silingardi E. J Pharm Biomed Anal. 2021;201:114093. doi: 10.1016/j.jpba.2021.114093.
- 73.Analysis of MT-45, a novel synthetic opioid, in human whole blood by LC-MS-MS and its identification in a drug-related death. Papsun D, Krywanczyk A, Vose JC, Bundock EA, Logan BK. J Anal Toxicol. 2016;40:313–317. doi: 10.1093/jat/bkw012.
- 74.A case study involving U-47700, diclazepam and flubromazepam-application of retrospective analysis of HRMS data. Partridge E, Trobbiani S, Stockham P, Charlwood C, Kostakis C. J Anal Toxicol. 2018;42:655–660. doi: 10.1093/jat/bky039.
- 75.Teens and spice: a review of adolescent fatalities associated with synthetic cannabinoid use. Paul AB, Simms L, Amini S, Paul AE. J Forensic Sci. 2018;63:1321–1324. doi: 10.1111/1556-4029.13704.
- 76.A two fatal cases of poisoning involving new cathinone derivative PV8. Pieprzyca E, Skowronek R, Korczyńska M, Kulikowska J, Chowaniec M. Leg Med (Tokyo) 2018;33:42–47. doi: 10.1016/j.legalmed.2018.05.002.
- 77.Fatal Intoxication with α-PVP, a synthetic cathinone derivative. Potocka-Banaś B, Janus T, Majdanik S, Banaś T, Dembińska T, Borowiak K. J Forensic Sci. 2017;62:553–556. doi: 10.1111/1556-4029.13326.
- 78.U-47700: a not so new opioid. Rohrig TP, Miller SA, Baird TR. J Anal Toxicol. 2018;42:0–4. doi: 10.1093/jat/bkx081.
- 79.New challenges in toxicology of new psychoactive substances exemplified by fatal cases after UR-144 and UR-144 with pentedrone administration determined by LC-ESI-MS-MS in blood samples. Rojek S, Korczyńska-Albert M, Kulikowska J, Kłys M. Arch Med Sadowej Kryminol. 2017;67:104–120. doi: 10.5114/amsik.2017.71452.
- 80.Identification and physicochemical characterization of 4-fluorobutyrfentanyl (1- ((4-fluorophenyl)(1-phenethylpiperidin-4-yl)amino)butan-1-one, 4-FBF) in seized materials and post-mortem biological samples. Rojkiewicz M, Majchrzak M, Celiński R, Kuś P, Sajewicz M. Drug Test Anal. 2016;9:405–414. doi: 10.1002/dta.2135.
- 81.Nitazenes: an old drug class causing new problems. Schwarz ES, Dicker F, Lothet E, Spungen H, Levine M. https://pmc.ncbi.nlm.nih.gov/articles/PMC12331301/ Mo Med. 2025;122:329–333.
- 82.New psychoactive substances: a review and updates. Shafi A, Berry AJ, Sumnall H, Wood DM, Tracy DK. Ther Adv Psychopharmacol. 2020;10:2045125320967197. doi: 10.1177/2045125320967197.
- 83.Death after use of the synthetic cannabinoid 5F-AMB. Shanks KG, Behonick GS. Forensic Sci Int. 2016;262:0–4. doi: 10.1016/j.forsciint.2016.03.004.
- 84.Qualitative identification of fentanyl analogs and other opioids in postmortem cases by UHPLC-ion trap-MSn. Shoff EN, Zaney ME, Kahl JH, Hime GW, Boland DM. J Anal Toxicol. 2017;41:484–492. doi: 10.1093/jat/bkx041.
- 85.Steep increases in fentanyl-related mortality west of the Mississippi river: recent evidence from county and state surveillance. Shover CL, Falasinnu TO, Dwyer CL, et al. Drug Alcohol Depend. 2020;216:108314. doi: 10.1016/j.drugalcdep.2020.108314.
- 86.Strategic decision-making by a forensic toxicology laboratory in response to an emerging NPS: detection, quantitation and interpretation of carfentanil in death investigations in Ontario, Canada, July 2017 to June 2018. Solbeck P, Woodall KL, Martin TL. J Anal Toxicol. 2021;45:813–819. doi: 10.1093/jat/bkab079.
- 87.Postmortem distribution and redistribution of MDAI and 2-MAPB in blood and alternative matrices. Staeheli SN, Boxler MI, Oestreich A, Marti M, Gascho D, Bolliger SA. Forensic Sci Int. 2017;279:83–87. doi: 10.1016/j.forsciint.2017.08.007.
- 88.Another fatal case related to the recreational abuse of U-47700. Strehmel N, Dümpelmann D, Vejmelka E, Strehmel V, Roscher S, Scholtis S, Tsokos M. Forensic Sci Med Pathol. 2018;14:531–535. doi: 10.1007/s12024-018-0018-3.
- 89.Toxicological investigations in a death involving 2-MAPB. Theofel N, Budach D, Vejmelka E, Scholtis S, Tsokos M. Forensic Sci Med Pathol. 2021;17:317–321. doi: 10.1007/s12024-021-00366-0.
- 90.A fatal case involving N-ethyldeschloroketamine (2-oxo-PCE) and venlafaxine. Theofel N, Möller P, Vejmelka E, Kastner K, Roscher S, Scholtis S, Tsokos M. J Anal Toxicol. 2019;43:0–6. doi: 10.1093/jat/bky063.
- 91.Emergence of cumyl-PEGACLONE-related fatalities in the northern territory of Australia. Tiemensma M, Rutherford JD, Scott T, Karch S. Forensic Sci Med Pathol. 2021;17:3–9. doi: 10.1007/s12024-020-00334-0.
- 92.Blood concentrations of a new psychoactive substance 4-chloromethcathinone (4-CMC) determined in 15 forensic cases. Tomczak E, Woźniak MK, Kata M, Wiergowski M, Szpiech B, Biziuk M. Forensic Toxicol. 2018;36:476–485. doi: 10.1007/s11419-018-0427-8.
- 93.Identification of novel psychoactive substances 25B-NBOMe and 4-CMC in biological material using HPLC-Q-TOF-MS and their quantification in blood using UPLC-MS/MS in case of severe intoxications. Wiergowski M, Aszyk J, Kaliszan M, Wilczewska K, Anand JS, Kot-Wasik A, Jankowski Z. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1041-1042:1–10. doi: 10.1016/j.jchromb.2016.12.018.
- 94.Two fatalities involving mebroqualone. Woods KM. J Anal Toxicol. 2021;45:308–311. doi: 10.1093/jat/bkaa077.
- 95.A fatal poisoning case by intravenous injection of “bath salts” containing acetyl fentanyl and 4-methoxy PV8. Yonemitsu K, Sasao A, Mishima S, Ohtsu Y, Nishitani Y. Forensic Sci Int. 2016;267:0–9. doi: 10.1016/j.forsciint.2016.08.025.
- 96.Quantification of 5F-CUMYL-P7AICA in blood and urine from an authentic fatality associated with its consumption by UHPLC-MS/MS. Zawadzki M, Chłopaś-Konowałek A, Nowak K, Wachełko O, Szpot P. Forensic Toxicol. 2020;39:240–247.
- 97.Next generation of novel psychoactive substances on the horizon - a complex problem to face. Zawilska JB, Andrzejczak D. Drug Alcohol Depend. 2015;157:1–17. doi: 10.1016/j.drugalcdep.2015.09.030.